New registry for corneal collagen cross-linking

Our experience over the last 10 years with the corneal collagen cross-linking treatment (CXL) of keratoconus shows that this procedure is both safe and effective in halting the progression of the keratoconus.  We also know that the earlier this procedure is offered, the more likely it is to retard keratoconus progression.  The other benefit from the CXL treatment is that – not surprisingly – it appears to be reducing the incidence of corneal transplantion for patients with keratoconus.  Just recently, there have also been changes in the treatment regime such that the UVA radiation can now be applied at a greater intensity for a shorter duration (most commonly 10 minutes rather than the 30 minutes which was previously required), hence making the procedure less stressful and disconcerting for the patient.


Now, in an exciting development, the world’s first corneal collagen cross-linking registry has been launched at the Save Sight Institute in Sydney.  The registry will collect and analyse clinical data and patient outcomes for the CXL treatment, making it the first large-scale assessment of corneal collagen cross-linking in the world.  Ophthalmologists from all over the world will be participating and contributing to this registry, which is being headed up by one of Australia’s leading corneal specialists Professor Stephanie Watson.  Keratoconus Australia – who have also provided support and funding for the registry – are very pleased that patient reported outcomes have been included in the format of the registry.  Feedback from patients is very important and this was a major factor in the move towards the shorter duration time (as outlined above) for the CXL treatment.